Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

News Briefs: Updates From Around The Industry

This article was originally published in The Gray Sheet

Executive Summary

Device industry news on Dec. 2 includes an IDE approval to study a super-small neurostimulator to treat face pain; distribution agreements in diabetes and blood processing; a product approval; and new legislation focused on telemedicine.

You may also be interested in...



Medtronic Builds Toward Integrated Care With A String Of Diabetes Deals

Medtronic inking four diabetes deals in about a month's time is no coincidence. The company wants to transform itself from a device maker that sells mostly to type 1 diabetics, into an integrated-care company that serves the broader diabetes community, and it does not have all the capabilities it needs to accomplish that feat in house, explains Hooman Hakami, who heads Medtronic's diabetes unit.

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

CBD Health Benefits More Attractive To Women? FDA Prioritizes Research Into Utero Effects

Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA  neuroscientist Andrew Shen.

Topics

Related Companies

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel